This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
|Industry||Health, Assistive technology|
|Headquarters||Har Hotzvim, Jerusalem, Israel|
Prof Amnon Shashua
(Executive VP of R&D)
|Products||OrCam MyEye and OrCam MyReader|
Number of employees
OrCam Technologies Ltd. is an Israeli-based company producing wearable artificial intelligence space. OrCam develops and manufactures assistive technology devices for individuals who are visually impaired, partially sighted, blind, print disabilities, or have other disabilities. OrCam headquarters is located in Jerusalem operating under the company name OrCam Technologies Ltd.
OrCam Technologies Ltd was founded in 2010 by Professor Amnon Shashua and Ziv Aviram. Before co-founding OrCam, the two in 1999 co-founded Mobileye, an Israeli company that develops vision-based advanced driver-assistance systems (ADAS) providing warnings for collision prevention and mitigation, which was acquired by Intel for $15.3 billion in 2017. OrCam launched OrCam MyEye in 2013 after years of development and testing, and began selling it commercially in 2015. In its early years, the company raised $22 million, $6 million of which from Intel Capital. In March 2017, OrCam had raised $41 million in capital, making it worth $600 million. Today, OrCam has over 150 employees, is headquartered in Jerusalem, and has offices in New York, Toronto, and London.
OrCam Technologies Ltd has created three devices; OrCam MyEye 2.0, OrCam MyEye 1, and OrCam MyReader.
OrCam My Eye 2.0:
- OrCam debuted the second-generation model, the OrCam MyEye 2.0 in December 2017.
- About the size of a finger, the MyEye 2.0 is battery-powered, and has been compressed into a self-contained device.
- The device snaps onto any eyeglass frame magnetically.
- Orcam 2.0 is smaller and lighter (only 22.5 grams/0.8 ounces) with more functionality to restore independence to the visually impaired.
JAMA Opthomology: In 2016 JAMA Opthomology conducted a study involving 12 legally blind participants to evaluate the usefulness of a portable artificial vision device (OrCam) for patients with low vision. The results showed that the OrCam device improved the patient’s ability to perform tasks simulating those of daily living, such as reading a message on an electronic device, a newspaper article or a menu.
Wills Eye: Wills Eye was a clinical study designed to measure the impact of the OrCam device on the quality of life of patients with End-stage Glaucoma. The conclusion was that OrCam, a novel artificial vision device using a mini-camera mounted on eyeglasses, allowed legally blind patients with end-stage glaucoma to read independently, subsequently improving their quality of life.
- 2018 Last Gadget Standing Winner 
- 2018 CES Innovation Awards Honoree in Accessible Tech
- 2017 NAIDEX Innovation Award 
- 2016 Louise Braille Corporate Recognition Award
- 2016 Silmo-d-Or Award 
- Vision Aware
- "After sale to Intel, Mobileye's founder raises sights on IPO for OrCam". 30 March 2017. Retrieved 8 February 2018 – via Reuters.
- CBS New York
- "Last Gadget Standing". lastgadgetstanding.com. Retrieved 13 February 2018.
- "CES Tech Events". ces.tech. Retrieved 8 February 2018.
- "Naidex". Naidex. Retrieved 8 February 2018.
- "Winners 2016". en.silmoparis.com. Retrieved 8 February 2018.